Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 21:52:33 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
You may also like
- Australia, New Zealand send planes to evacuate nationals from New Caledonia
- Enchanting Sydney's streets with Chinese music
- National Women's Housekeeping Service Competition Concludes, Winners Awarded
- ACWF Holds Video Meeting to Study Law on Safeguarding National Security in HK SAR
- Cruise worker 'murders newborn son on board ship': Shocked co
- ACWF Launches Campaign to Care for Children in Winter Vacation
- 20 Women Model Medical Workers in Anti
- Social media could be BANNED for under
- My fiancé died on the morning of our wedding day